CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text

Medicine, Immunology, Oncology +17

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Medicine, Genetics, Hematology +14

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy

Elena Sotillo, David M. Barrett, Kathryn L. Black et al. · Cancer Discovery · 2015 · 1.3K citations · Full text

Life Sciences, Hematology, Molecular Biology +15

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Rebecca Gardner, David Wu, Sindhu Cherian et al. · Blood · 2016 · 749 citations · Full text

Life Sciences, Hematology, Immunology +14